Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

The Medical Device Co. That’s on the Cutting-Edge of Advancing Heart Disease Treatment

Back in early September , we introduced our Stockhouse audience to a unique play in the emerging medical tech space – Neovasc Inc. ( TSX: NVCN , OTCQB: NVCN , Forum ). The company develops, manufactures, and markets products for the rapidly growing cardiovascular marke...
Dave Jackson | November 29, 2021 |

Revolutionizing vascular grafting with a durable solution

Our next guest is a multi-technology biomedical company, focused on the development and commercialization of medical technologies. Marizyme Inc. (OTCQB:MRZM) has had its sights set on development of medical technology and products, one of which is DuraGraft. J...
Brieanna McCutcheon | September 27, 2023 |

Hemostemix Founder: A Man with a Compassionate Heart

The Canadian stem cell company Hemostemix Inc. ( TSX-V: HEM , OTC: HMTXF ) was founded by a man who truly had a compassionate heart and a clear intent to establish a breakthrough in heart disease using the same technology that saved his life. Roger Bergersen, who train...
Featured Submission | December 14, 2020 |

Midnight Sun Mining is in the heart of the Zambian-Copper Belt

TMH: Midnight Sun Mining Corp. (TSXV:MMA) has an extensive land package in the heart of the Zambian-Copper Belt. The company’s site sits next to the largest copper mine in Africa consisting of multiple discoveries, so we asked Al Fabbro, president and CEO...
Brieanna McCutcheon | June 20, 2023 |

“A Low Risk Gold Opportunity” in the Heart of Nevada’s Elephant Country

Back in July , Stockhouse Editorial introduced our audience to Nevada’s newest and fastest-growing gold miner – i-80 Gold Corp. ( TSX.IAU , OTC: IAUCF , Forum ). In a recent exclusive video Q&A podcast, Stockhouse Media’s Dave Jackson wa...
Dave Jackson | September 26, 2021 |

Shaping the Future of Medicine by Delivering Regenerative Medicines

(Click image to play video) Envision a chest pain that feels like the most severe form of heartburn you ever experienced before. This is one of the main symptoms of ischemia – a disease which millions of people around the globe live with every day. Treati...
Dave Jackson | December 8, 2020 |

Mining Exploration in the Presence of Giants, in the Heart of the Golden Triangle

There’s been a lot of buzz on Stockhouse about the vigorous renewal of major mining operations going on in a prolific, but underexplored, region of British Columbia. And one junior explorer is developing what they believe "has the potenti...
Dave Jackson | November 17, 2020 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |
1 2 3 4 5 6 7 8 9 10 ...